Stockwinners Market Radar for December 27, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EST Cathie Wood's ARK Investment bought 10.8K shares of Crispr Therapeutics today

19:41 EST Zscaler director buys $543.9K in common stock - In a regulatory filing, Zscaler disclosed that its director Andrew Brown bought 5K shares of common stock on December 23 in a total transaction size of $543.9K.

19:39 EST Lockheed Martin and ERAPSCO awarded $222.5M U.S. Navy contract modification - ERAPSCO and Lockheed Martin are awarded firm-fixed-price modifications to a previously awarded indefinite-delivery/indefinite-quantity contract. These modifications exercise options for the production and delivery of up to 36,000 AN/SSQ-125A series production sonobuoys for the Navy. The estimated aggregate ceiling for all modifications is not-to-exceed $222,459,840, with the companies having an opportunity to compete for individual orders.

18:50 EST Mercurity Fintech Holding to sell $5M in company units - Mercurity Fintech "announced that on December 23, 2022, in connection with its private investment in public equity financing, it entered into a Securities Purchase Agreement with an accredited non-U.S. investor to offer and sell the Company's units, each consisting of one ordinary share and three Warrants for total gross proceeds of $5 million. The closing of this third PIPE financing together with the consummation of the first and second PIPE financing would yield total gross proceeds of $13.15 million invested in the Company's shares and warrants by third parties in the second half of 2022. The Company expects to use the net proceeds from the three rounds of PIPE financing to develop its Web3 and blockchain infrastructure, expand its consultation services, and pursue the licensure for cryptocurrency from New York State Department of Financial Services although the Company cannot provide any assurance on actually obtaining the "BitLicense" in the near future or at all."

17:44 EST Ampio regains compliance with NYSE listing standards - Ampio Pharmaceuticals "announced that it has received notification from The NYSE American LLC stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide."

17:06 EST Grove Collaborative refinances existing debt, extends maturity - Grove Collaborative Holdings "announced that it has entered into a new Loan and Security Agreement providing for a four-year $72.0 million term loan. With this transaction, Grove also welcomes two capital partners with deep experience in consumer, disruptive commerce, and ESG to its capitalization table, Structural Capital and Avenue Sustainable Solutions Fund, L.P. The new funds will be used to refinance existing debt and to fund ongoing business operations as Grove continues to push to profitability. The term loan bears an annual interest at the greater of 15% or prime plus 7.5%, payable monthly. The principal repayment period commences in July 2025 and the term loan matures in December 2026."

17:01 EST NuZee to effect 1-for-35 reverse stock split - NuZee "announced that it intends to effect a 1-for-35 reverse stock split of its issued and outstanding shares of common stock. As previously disclosed, at the Company's Special Meeting of Stockholders held on December 9, 2022, the stockholders of the Company approved a reverse stock split of the Company's issued and outstanding shares of its common stock and authorized the Board of Directors to select the ratio of the reverse stock split within a range from 1-for-10 to 1-for-50. The Board has since exercised such discretion to effect a 1-for-35 reverse stock split. The reverse stock split will become effective on Wednesday, December 28, 2022 upon filing with the Nevada Secretary of State of an amendment to the Company's articles of incorporation."

16:56 EST Tesla debuts Wireless Charging Platform, 'inspired' by Cybertruck design - "Inspired by the angular design and metallic styling of Cybertruck, our Wireless Charging Platform provides 15W of fast charging power per device for up to three devices simultaneously. Its sleek design is composed of an aluminum housing, premium alcantara surface and a detachable magnetic stand that allows you to lay the charger flat or at an angle for better viewing. Featuring FreePower technology, which charges your Qi capable devices such as phones or earbuds placed anywhere on its surface without precise alignment," said Tesla in a product introduction on its website. Reference Link

16:41 EST LivePerson names three new directors as part of prior deal with Starboard - LivePerson "announced that Vanessa Pegueros, Bruce Hansen and Yael Zheng have been appointed as independent members of the Company's Board of Directors, pursuant to the previously announced agreement with Starboard Value. With these appointments, LivePerson's Board will comprise nine directors, eight of whom will be independent and nearly half of whom have joined the Board in the past two years. These appointments were unanimously approved by the LivePerson Board."

16:32 EST Marathon Oil completes acquisition of Ensign's Eagle Ford assets - Marathon Oil (MRO) announced the completion of its acquisition of the Eagle Ford assets of Ensign Natural Resources for a total cash consideration of $3B after taking into account closing adjustments. The acquisition was previously announced on November 2. "We are pleased to announce the close of our acquisition of Ensign's high-quality assets in the core of the Eagle Ford Shale," said chairman, president, and CEO Lee Tillman. "This acquisition satisfies every element of our disciplined acquisition criteria. It's immediately accretive to our key financial metrics, it will drive higher shareholder distributions consistent with our operating cash flow driven Return of Capital framework, it's accretive to our inventory life with attractive locations that immediately compete for capital, and it offers truly compelling industrial logic given our existing Eagle Ford footprint and our track record of execution excellence in the play."

16:23 EST Kala Pharmaceuticals jumps 64% after FDA accepted application for KPI-012

16:16 EST Macondray Capital Acquisition I to redeem shares, liquidate and dissolve - Macondray Capital Acquisition I "announced that, because the Company will not consummate an initial business combination within the time period required by its Second Amended and Restated Memorandum and Articles of Association, the Company intends to liquidate and dissolve in accordance with the provisions of the Amended Articles, effective as of the close of business on January 6, 2023, and will redeem all of the outstanding Class A ordinary shares that were included in the units issued in its initial public offering, at an anticipated per-share redemption price of approximately $10.00. As of the close of business on January 6, 2023, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount."

16:10 EST Forrester reducing San Francisco office space, sees $5M-$6M charge - Forrester Research announced that it would close one floor of its offices located at 150 Spear Street, San Francisco, California. The space had been vacant prior to the company electing to permanently reduce its office space. The company anticipates incurring a non-cash asset impairment charge in the range of $5M to $6M in Q4 in connection with this reduction in space.

16:04 EST Clene drops 20% to 81c after COVID study failure

16:03 EST Clene says Phase 2 COVID study showed no clinical benefit - Clene announced topline study results from its Phase 2 investigational trial with CNM-ZnAg, an ionic solution of zinc and silver, for the treatment of non-hospitalized acutely symptomatic participants infected with COVID-19. The Phase 2 multicenter, randomized, double-blind, placebo-controlled trial assessed the efficacy and safety of CNM-ZnAg in COVID-19 infected participants in Brazil. Study participants were randomized 1:1:2 to receive daily low dose CNM-ZnAg, high dose CNM-ZnAg, or placebo in addition to standard supportive care for up to 21 days. The primary endpoint assessed the time to substantial alleviation of COVID-19 symptoms through 28 days. No clinical benefit was observed versus placebo, the company said. CNM-ZnAg was safe and well-tolerated, and no safety signals were identified, it added. Rob Etherington, Clene's CEO, commented, "While COVID has not been a therapeutic focus of the company, we were compelled to explore the potential of CNM-ZnAg to help address the global pandemic. At this time, we will cease further development for COVID. We are heartened by the safety profile of CNM-ZnAg, the second asset developed through our technology platform, and its future potential in other antiviral and antibacterial areas. We continue our focus on treatment of neurodegenerative diseases with our lead asset, CNM-Au8, which is advancing towards registrational trials."

15:33 EST Southwest sees flying roughly one third of schedule for 'next several days'

15:21 EST Southwest says it continues 'recovering from operational challenges' - Southwest issued the following update on its website: "With consecutive days of extreme winter weather across our network behind us, continuing challenges are impacting our Customers and Employees in a significant way that is unacceptable. And our heartfelt apologies for this are just beginning. We're working with Safety at the forefront to urgently address wide-scale disruption by rebalancing the airline and repositioning Crews and our fleet ultimately to best serve all who plan to travel with us. We were fully staffed and prepared for the approaching holiday weekend when the severe weather swept across the continent, where Southwest is the largest carrier in 23 of the top 25 travel markets in the U.S. These operational conditions forced daily changes to our flight schedule at a volume and magnitude that still has the tools our teams use to recover the airline operating at capacity. This safety-first work is intentional, ongoing, and necessary to return to normal reliability, one that minimizes last-minute inconveniences. As we continue the work to recover our operation, we have made the decision to continue operating a reduced schedule by flying roughly one third of our schedule for the next several days... Our Employees and Crews scheduled to work this holiday season are showing up in every single way. We are beyond grateful for that. Our shared goal is to take care of every single Customer with the Hospitality and Heart for which we're known. On the other side of this, we'll work to make things right for those we've let down, including our Employees. With no concern higher than ultimate Safety, the People of Southwest share a goal to take care of each and every Customer. We recognize falling short and sincerely apologize." Reference Link

12:50 EST Lightjump Acquisition Corp trading resumes

12:00 EST Azul falls -8.6% - Azul is down -8.6%, or -56c to $6.00.

12:00 EST Signa Sports falls -10.6% - Signa Sports is down -10.6%, or -40c to $3.37.

12:00 EST Global Blue rises 13.2% - Global Blue is up 13.2%, or 53c to $4.54.

11:34 EST Imax crosses $100M in global box office with 'Avatar: The Way of Water' - Imax Corporation (IMAX) announced that Disney (DIS) and Lightstorm's "Avatar: The Way of Water" has now earned $105.5M in Imax global box office in less than two weeks, making it "the fastest film to hit the $100 million mark in Imax since April 2019" and "only the ninth film in Imax history to exceed $100 million in global box office." To date, Imax has accounted for 11.4% of the film's global gross on "only a fraction of its total screens," the company stated in a press release. "Avatar: The Way of Water" will screen across Imax locations in most global markets through January. The film debuted with the widest Imax global release of all time across 1,543 screens and is available exclusively in Imax 3D in Imax locations worldwide, the company added. "'Avatar: The Way of Water' is showing the strong endurance at the global box office we expected, particularly with its phenomenal performance internationally where several key markets grew their grosses over opening weekend. In just over a week of release, 'Avatar: The Way of Water' has sailed to more than $100 million in IMAX box office with no signs of slowing down, as our screens remain the destination of choice to experience this one-of-a-kind film," said Rich Gelfond, CEO of Imax.

10:00 EST Companhia Brasileira de Distribuicao falls -8.4% - Companhia Brasileira de Distribuicao is down -8.4%, or -29c to $3.18.

10:00 EST Studio City rises 6.3% - Studio City is up 6.3%, or 34c to $5.63.

10:00 EST Turkcell rises 7.9% - Turkcell is up 7.9%, or 35c to $4.79.

09:47 EST Natura &Co falls -7.3% - Natura &Co is down -7.3%, or -32c to $4.09.

09:47 EST Companhia Brasileira de Distribuicao falls -9.2% - Companhia Brasileira de Distribuicao is down -9.2%, or -32c to $3.15.

09:47 EST Turkcell rises 6.3% - Turkcell is up 6.3%, or 28c to $4.72.

09:46 EST Kalera PLC trading halted, volatility trading pause

09:12 EST Abbott to upgrade 75 primary health centers across India - Abbott has committed to upgrading 75 Primary Health Centres, PHCs, to Health and Wellness Centres, HWCs, across nine States in India in partnership with Americares India Foundation, a health-focused relief and development organization. The HWC program, supported by an Abbott grant of about $2.4M, will serve over 2.5 million people from under-resourced communities every year. These centres are vital to support the government's Ayushman Bharat initiative, advancing access to affordable, quality healthcare equitably across the population. Jasraj Virdi, Global Citizenship and Sustainability Director, Abbott, said, "In line with our 2030 Global Sustainability Plan, we intend to expand affordable access to healthcare by delivering innovative, decentralized models of care that advance prevention and early diagnosis, and provide quality treatment and care. Strengthening local health centres to be well equipped to meet community healthcare needs is a step in this direction. And these centres will also play an integral role in supporting the government's health initiatives to ensure the delivery of quality primary healthcare that is affordable, equitable and sustainable."

09:08 EST Camber Energy signs agreement to acquire private oil companies - Camber Energy announced that it entered into an agreement to acquire all of the issued and outstanding membership interests of certain privately-owned companies which in turn own interests in certain oil and gas properties and related equipment and other tangible personal property, including working interests in approximately one hundred sixty nine proved producing oil wells, one hundred seventy four proved non-producing wells and twelve proved undeveloped well locations. The wells produce hydrocarbons from known geological formations and reservoirs, and the seller's internal estimates of the remaining oil reserves based on recent NYMEX strip pricing, historical production rates, historical lease operating expenses and transportation differentials, indicate a total proved reserve value, on a PV10 basis, of approximately USD$185 million as at January 1, 2023.

09:05 EST Inspira Technologies signs strategic OEM agreement with Terumo - Inspira Technologies (IINN) announced that it has signed an exclusive OEM, Original Equipment Manufacturing, agreement with Terumo Cardiovascular, a division of Terumo Corporation (TRUMY), a leading global medical device company. Terumo Corporation operates in over 160 countries and regions around the world, providing patients in a variety of medical settings with over 50,000 products and services. Joe Hayon, Inspira Technologies' Co-Founder and President stated: "This is a very important agreement for the Company, and we believe that it is in line with our strategy towards developing collaborations with the largest medical device companies to join in on our journey to market."

09:01 EST Arthur J. Gallagher acquires ROC Group - Arthur J. Gallagher & Co. announced the acquisition of Chicago-based ROC Group. Terms of the transaction were not disclosed. "ROC Group is a leading employee communication firm with an outstanding culture, and their products and services complement our existing benefits and HR offerings," said J. Patrick Gallagher, Jr., Chairman, President and CEO. "I am delighted to welcome Jan and her associates to Gallagher."

09:00 EST PolarityTE trading resumes

08:42 EST My Size regains compliance with Nasdaq minimum closing bid price rule - My Size reported the receipt of a formal notification from The Nasdaq Stock Market that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's common stock to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's common stock was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.

08:39 EST PolarityTE to resume trading at 9:00 am ET - PolarityTE will resume trading at 9:00 am ET, with quotation set to resume at 8:55 am ET, according to Nasdaq. The stock was halted with news pending ahead of the company announcing that it signed a non-binding letter of intent with Michael Brauser for him to make an offer to acquire 100% of the outstanding equity interests of the company at a proposed offering price of $1.03 per common share in cash.

08:38 EST ChromaDex: NR supplementation significantly increased NAD+ levels in NEVs - ChromaDex announced promising new findings based on a previously published clinical trial of company's proprietary Niagen ingredient , which was supported by the ChromaDex External Research Program CERP . The new study, published in the peer-reviewed journal Aging Cell, was led by Dr. Christopher R. Martens, Department of Kinesiology & Applied Physiology, University of Delaware, USA, in collaboration with scientists from the National Institute on Aging . The study investigated whether NR would positively augment nicotinamide adenine dinucleotide levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles found in blood plasma. NEVs are nano-sized particles that are released by neurons in the central nervous system, including the brain, and circulate in blood plasma. They can contain RNA, DNA, and/or proteins that provide information relating to the metabolism of their tissue of origin, and serve as signaling molecules between various cells, tissues, or organs. Some scientists are investigating extracellular vesicles as biomarkers of disease development and progression. The present study demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Ass42, a biomarker for Alzheimer's disease . "We believe biomarkers of brain health are continuing to develop and will be of great importance as humans live longer, especially as age is the number one risk factor for most conditions seen in older adults," said Rob Fried, CEO of ChromaDex. "Further, this study builds upon a previous breakthrough clinical study we recently announced, which we believe demonstrated the promising effects of NR supplementation on Parkinson's disease patients and will pave the way for future brain-related research."

08:34 EST Aspira sees CMS covering multi-marker tests for ovarian cancer in spending bill - Aspira Women's Health announced that the 2023 Omnibus Spending Bill passed by Congress and awaiting President Biden's signature contains language directing the Center for Medicare & Medicaid Services to cover multi-marker tests for ovarian cancer. The company believes all of its commercially available ovarian cancer risk assessment blood tests would fall under the recommended coverage expansion, which is expected to significantly increase access for women with pelvic masses in both Medicare and Medicare Advantage plans. It also sets the stage for commercial payers to adopt similar coverage policies. Aspira also announced that it has expanded Ova1Plus Medicaid access in five states during 2022 including: Virginia, Alabama, Maine, Pennsylvania, and Rhode Island. Broadening Medicaid coverage is consistent with the Company's goal of making OvaSuite products available and affordable to all women regardless of socioeconomic status. Aspira has now secured Medicaid coverage in 27 states, representing 77% of Medicaid lives. Lastly, the Company announced the American Medical Association has approved a new Proprietary Laboratory Assay code for OvaWatch, the Company's recently launched non-invasive ovarian cancer risk assessment for use in the initial clinical assessment of adnexal masses. The PLA code will be used to bill all payers effective April 1. A PLA code uniquely identifies OvaWatch, distinguishing it from other tests and allowing for a more streamlined reimbursement process.

08:11 EST NextDecade announces SPA with Enn LNG - NextDecade announced a volume increase of the sale and purchase agreement, or SPA, with Enn LNG Pte Ltd, a wholly-owned subsidiary of ENN Natural Gas Co., Ltd. for the supply of liquefied natural gas (LNG) from NextDecade's Rio Grande LNG export project in Brownsville, Texas. Under the 20-year SPA, ENN will now purchase 2.0 million tonnes per annum of LNG. This is a 0.5 MTPA increase from the original 1.5 MTPA SPA announced earlier this year. All volumes of LNG are indexed to Henry Hub and will be supplied from the first three trains at RGLNG on a free-on-board basis. NextDecade is currently targeting a positive Final Investment Decision (FID) on the first three trains of the RGLNG export project during the first quarter of 2023, with FIDs of its remaining trains to follow thereafter.

08:08 EST Catalyst Biosciences, GNI Group complete first step in reverse merger plan - Catalyst Biosciences announced that the parties have signed definitive agreements for the sale and purchase of GNI's proprietary new chemical entity F351 program. F351 has shown clinical efficacy as a treatment for both liver and kidney fibrosis. In a separate independent transaction, GNI and other minority stockholders will, subject to stockholder approval and certain customary closing conditions, exchange their controlling interest in Beijing Continent, a commercial-stage pharmaceutical company based in China and majority-owned subsidiary of GNI, for newly issued shares of Catalyst. Catalyst will continue to trade on Nasdaq under the ticker symbol "CBIO" after both transactions. Continent is the first marketer of pirfenidone in China for idiopathic pulmonary fibrosis, which was approved in China in 2011. Continent recorded sales of $73M in the nine months ended September 30. Continent has operated profitably during the last five years while funding a clinical pipeline focused on other fibrosis indications, including F351 for hepatitis B virus, or HBV-associated fibrosis and non-alcoholic steatohepatitis, or NASH. In conjunction with these transactions, CBIO will distribute $7.5M on January 12, 2023 as a special dividend and grant a non-transferable, each to stockholders of record on January 5, 2023. The CVR entitles stockholders of record to future dividends associated with the monetization of Catalyst intellectual property and other assets, including additional potential cash distributions. Catalyst expects the ex-dividend date for its common stock to be January 13, 2023. This distribution follows a previous distribution of $45M in September. The company expects to make one or more additional distributions through the CVR in 2023. The acquisition of F351, consummated concurrently with the execution of the definitive asset purchase agreement, provides Catalyst with the global rights to F351 in consideration for 6,266,521 shares of common stock and 12,340 shares of a new series of preferred stock with economic rights equivalent to Catalyst's common stock. Each share of Series X preferred stock is convertible into 10,000 shares of common stock, subject to stockholder approval under Nasdaq rules and subject to a beneficial ownership conversion blocker. Both the conversion of the Series X preferred stock and the acquisition of a 65.18% interest in Continent will be subject to Catalyst stockholder approval, which will be sought in 2023. If the acquisition is approved by stockholders, Catalyst would issue at closing a total of up to 1,110,776,224 shares of common stock for a controlling interest in Continent, at which point Catalyst would expect to consolidate results of operations with Continent.

08:05 EST Amyris advances transaction for rights to supply two of its ingredients - Amyris announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris' ingredients. The transaction is subject to antitrust review under the Hart-Scott-Rodino Act, HSR, with a standard waiting period of thirty days. Accordingly, the transaction is expected to sign and close early in the first quarter of 2023. Both parties have agreed to confidentiality regarding further details about the transaction during this period. The transaction, with an expected value of over $500M, is expected to follow a structure similar to those completed by Amyris in 2021, and include an exclusive worldwide license for the distribution, marketing and selling of two Amyris ingredients. Amyris would continue to develop, scale and manufacture the ingredients. In addition, the parties are expected to enter a long-term R&D collaboration partnership for the development of new molecules. "We are pleased with the strong continued growth across our core business. The power of our technology is evident, and we are very excited about the potential of this new partnership and the continued growth of the two ingredients," commented John Melo, President and Chief Executive Officer. "This is our third transaction of this nature and what we believe to be a strategic part of our business model for the value creation of our technology."

08:04 EST Disc Medicine receives FDA ODD for bitopertin - Disc Medicine announced that the U.S. Food and Drug Administration granted Orphan Drug Designation, ODD, to bitopertin for the treatment of erythropoietic protoporphyria. Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX, the toxic metabolite that causes disease pathology in EPP patients. It is currently being studied in two ongoing Phase 2 studies in EPP, AURORA and BEACON. "Receiving orphan drug designation for bitopertin is incredibly encouraging and validates our commitment to bring a potential new treatment to EPP patients," said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. "We are eagerly awaiting the results of our ongoing Phase 2 trials and look forward to collaborating with the FDA to progress bitopertin through clinical development." In August 2022, Disc announced it entered into a definitive merger agreement with Gemini Therapeutics.

08:00 EST Toyota reports November worldwide sales rose 2.9% to 796,484 units - Toyota reports that in November, both global sales and production exceeded the previous year's level "as a result of solid demand, primarily in North America, in addition to a rebound from the impact of parts supply shortages associated with the spread of COVID-19 in Southeast Asia in the previous year." Toyota added that the "situation remains difficult to predict due to semiconductor shortages and COVID-19. However, we will continue to carefully monitor the parts supply situation and minimize sudden decreases in production as much as possible while making every effort to deliver as many vehicles to our customers at the earliest date." Toyota reported worldwide sales of 796,484 units in November, up 2.9% from last year. Toyota reported worldwide production reached a "record high" of 833,104 units, up 1.5 from last year. Toyota Motor Corporation also announced the cumulative total from January to November, including those for subsidiaries Daihatsu Motor and Hino Motors. Reference Link

07:53 EST KalVista jumps 10% to $5.60 per share after announcing $58M registered offering

07:34 EST Dogness International regains compliance with NASDAQ minimum bid price - Dogness Corporation announced that on December 23, 2022, the Company received notification from The Nasdaq Stock Market confirming it has cured the minimum bid price deficiency regaining compliance with Listing Rule 5450(a)(1) and this matter is now closed.

07:09 EST RYAM's Jesup facility impacted by outage, may reduce EBITDA - Rayonier Advanced Materials announced that its facility at Jesup, Georgia has been impacted by a force majeure declared by its natural gas provider, Southern Natural Gas Company due to an unscheduled outage of the Elba Express Pipeline's Hartwell Compressor Station. Southern Natural Gas Company's notice of this Event can be found at: Southern Natural Gas Company has asserted that, during the period of the SNG Force Majeure Event, which commenced on December 24 RYAM's Jesup facility will be subject to a financial penalty for each MMBtu of natural gas consumed in excess of a contractually allocated amount. Based on this and other current assumptions, the Company expects the Event could reduce EBITDA by approximately $775,000 to $900,000 per day. Accordingly, if the SNG Force Majeure Event were to continue through the end of 2022, the Company estimates that its aggregate EBITDA would be approximately $6 to $7M lower than it otherwise would have been without the financial penalty. The Company's facility at Fernandina Beach, Florida is not affected by the SNG Force Majeure Event. Prior to the SNG Force Majeure Event, the Company had expected that it would be able to achieve its guidance issued on November 1 that the Company's full-year Adjusted EBITDA is expected to exceed $175M, but the SNG Force Majeure Event may cause the Company's full-year Adjusted EBITDA to be below that amount. The Company expects to meet its Net Debt guidance of $725M or better.

07:04 EST ProFrac Holding to acquire REV Energy, Performance Holdings - ProFrac Holding reported that it has closed its previously-announced acquisition of the Eagle Ford sand mining operations of Monarch Silica and announced that it has entered into definitive agreements to acquire two companies that will grow its pressure pumping footprint and sand mine portfolio. The Company's subsidiary, ProFrac Holdings II has entered into a definitive agreement to acquire REV Energy Holdings, a privately owned pressure pumping service provider with operations in the Rockies and Eagle Ford. Under the terms of the agreement, ProFrac will acquire REV for $140M, consisting of $70M in ProFrac Class B common shares, approximately $39M in seller-provided financing, and the balance with cash on hand and debt assumption of approximately $5.5M. The purchase agreement also provides for up to $20 million of earn-out payments in the event REV achieves EBITDA of approximately $90 million in 2023. The transaction is expected to close before the end of January 2023. ProFrac also announced that its subsidiary, ProFrac Holdings II, LLC, has entered into a definitive agreement with Performance Holdings I, LLC and Performance Holdings II to acquire the largest in-basin proppant producer serving the Haynesville, for $475 million of cash. ProFrac expects the transaction to be accretive to earnings and free cash flow immediately upon closing. Based on preliminary discussions with capital providers, including existing and potential new lenders, as well as the Company's largest shareholders, ProFrac believes it will be positioned to fund the acquisition with a combination of new capital and cash from operations. Such preliminary discussions are non-binding, and the Company cannot assure that it will raise new capital from such discussions on a timely basis or otherwise. The Company expects the acquisition to close in the first quarter of 2023.

06:52 EST Buenaventura announces blockades near Julcani, Orcopampa mines ceased - Buenaventura advised that road blockades near the Julcani and Orcopampa mines have ceased completely and peacefully. There has been no damage to Buenaventura's property nor asset, allowing Julcani and Orcopampa to restart activities under normal operating conditions, also enabling the company to meet its 2022 production guidance.

06:36 EST Altus Power to acquire 220 MW of construction solar assets for $293M - Altus Power announced that it entered a definitive agreement to acquire approximately 220 megawatts , or MW, of newly developed and in construction solar assets for approximately $293M from funds managed by True Green Capital Management. Altus Power and TGC currently expect the transaction will close during first quarter of 2023 upon satisfaction of certain closing conditions. The company intends to fund the transaction with its long-term funding facility led by Blackstone Structured Finance and cash on hand. The acquired portfolio, once closed, will promptly add approximately 207 MW of commercial-scale solar assets to Altus Power's operations, with the remaining 13 MW in the final stages of construction and expected to be completed in the coming months. This portfolio offers additional scale in Altus Power's existing markets including California, Colorado, Illinois, Massachusetts, New Jersey, and New York and provides entry into two new markets of Delaware and South Carolina.

06:32 EST SpringsWorks Therapeutics completes submission of nirogacestat NDA to FDA - SpringWorks Therapeutics announced that the company has completed the submission of a new drug application, or NDA, to the FDA for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors. The NDA submission is being reviewed under the FDA's Real-Time Oncology Review, or RTOR, program and includes data from the Phase 3 DeFi trial, a global, randomized, double-blind, placebo-controlled trial in adult patients with desmoid tumors. The FDA previously granted Fast Track and Breakthrough Therapy designations to nirogacestat for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis. Nirogacestat has also received Orphan Drug designation from the FDA for the treatment of desmoid tumors and from the European Commission for the treatment of soft tissue sarcoma.

06:22 EST Argo Blockchain requests suspension of trading on Nasdaq - Argo Blockchain announced that it has requested a suspension of trading for its ADSs and unsecured notes traded on the Nasdaq Global Select Market as the London Stock Exchange is closed for trading on Tuesday, December 27. The company expects that trading on Nasdaq will resume on Wednesday, December 28 after the company makes an announcement that is expected to be released before opening of trading on Wednesday.

06:06 EST Nio cuts Q4 delivery view to 38,500-39,500 from 43,000-48,000 vehicles - Nio provided an updated delivery outlook for the fourth quarter of 2022. In December 2022, the company has been facing challenges in deliveries and productions, together with certain supply chain constraints, caused by the outbreak of the Omicron coronavirus variant in major cities in China. While our teams have strived to maintain continuous operations on all fronts, we were not able to reach our full capacities, particularly when there have been disruptions on delivery and registration procedures involving users. The company now expects to deliver 38,500 to 39,500 vehicles in the fourth quarter of 2022, adjusted from previously released outlook of 43,000 to 48,000 vehicles. The company said, "On December 24, 2022, the Company hosted NIO Day 2022 in Hefei, China and launched the EC7, a smart electric flagship coupe SUV, and the All-New ES8, an all-around smart electric flagship SUV, from NIO Technology 2.0 (NT2.0). The design of the EC7 interprets the power of elegance to the extreme extent. In the ES8, the unique layout of "four executive seats and one flexible third row" demonstrates the composed and generous style of the All-New ES8 as a flagship SUV. Both products further contribute to the diversity of competitive product offering, bringing user experiences beyond expectations in terms of design, performance, comfort, intelligence, safety, and sustainability. The EC7 and the All-New ES8 are expected to commence delivery in May and June 2023, respectively."

05:01 EST Nanobiotix randomizes first patient in NANORAY-312 trial - Nanobiotix announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy. NBTXR3 activated by radiotherapy will be evaluated alone or in combination with cetuximab. NBTXR3 is a potentially first-in-class radioenhancer with broad application across solid tumors, with prioritized focus in head and neck cancer.